Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: Evaluation of the long-term outcome

Clinical Lymphoma, Myeloma and Leukemia

Volumn 10, Issue 4, 2010, Pages 258-261

  Zinzani, Pier Luigi ^a   Gandolfi, Letizia ^a   Stefoni, Vittorio ^a   Fanti, Stefano ^b   Fina, Mariapaola ^a   Pellegrini, Cinzia ^a   Montini, Gian Carlo ^b   Derenzini, Enrico ^a   Broccoli, Alessandro ^a   Argnani, Lisa ^a   Pileri, Stefano ^a   Baccarani, Michele ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Follicular lymphoma; Non Hodgkin lymphoma; Pretreated indolent lymphoma; Radioimmunotherapy

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUDARABINE; IBRITUMOMAB TIUXETAN; IFOSFAMIDE; MITOXANTRONE; PREDNISONE; RITUXIMAB; VINCRISTINE; YTTRIUM 90; GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ANEMIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CLINICAL EVALUATION; DRUG EFFECT; DRUG SAFETY; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LONG TERM CARE; LYMPHOCYTOMA; MALE; MARGINAL ZONE LYMPHOMA; MONOTHERAPY; NEUTROPENIA; PANCYTOPENIA; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; CANCER COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; ISOTOPE LABELING; MAJOR CLINICAL STUDY; OUTPATIENT CARE; PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; RADIOIMMUNOTHERAPY; RETROSPECTIVE STUDY; SECOND CANCER;

EID: 77957092383     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.3816/CLML.2010.n.054     Document Type: Article

References (31)

1. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998; 16:2780-95.
2. Jaffe E, Harris N, Stein H. World Health Organization Classification of Tumours. Tumours of Haematopoietic and Lymphoid Tissues. Washington, DC: IARC Press; 2000.
3. Zinzani PL, D'Amore F, Bombardieri E, et al. Consensus conference: implementing treatment recommendations on yttrium-90 immunotherapy in clinical practice -report of a European workshop. Eur J Cancer 2008; 44:366-73.
4. Horning SJ. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 1993; 20:75-88.
5. Bartlett NL. 90Y-ibritumomab tiuxetan (Zevalin) radioimmunotherapy for transformed B-cell non-Hodgkin's lymphoma (NHL) patients. Presented at: the 38th Annual Meeting of the American Society of Clinical Oncology; May 18-21, 2002; Orlando, FL. Abstract 51.
6. Johnson PW, Rohatiner A, Whelan J, et al. Patterns of survival in patients with recurrent follicular lymphoma: A 20-year study form a single center. J Clin Oncol 1995; 13:140-7.
7. Bastion Y, Sebbon C, Berger F, et al. Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. J Clin Oncol 1997; 15:1587-94.
8. Zinzani PL. Salvage chemotherapy in follicular non-Hodgkin's lymphoma: focus on tolerability. Clin Lymphoma Myeloma 2006; 7:115-24.
9. Witzig TE, Gordon LI, Cabanillas F, et al. Randomised controlled trials of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus riruximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002; 20:2453-63.
10. Press OW. Radiolabeled antibody therapy of B-cell lymphomas. Semin Oncol 1999; 26:58-65.
11. Anderson KC, Bates MP, Slaughenhoupt BL, et al. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood 1984; 63:1424-33.
12. Chinn PC, Leonard JE, Rosenberg J, et al. Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for the treatment of non-Hodgkin's lymphoma. Int J Oncol 1999; 15:1017-25.
13. Gokhale AS, Mayadev J, Pohlman B, et al. Gamma camera scans and pretreatment tumor volumes as predictors of response and progression after Y-90 anti-CD20 radioimmunotherapy. Int J Radiat Oncol Biol Phys 2005; 63:194-201.
14. Witzig TE, White CA, Wiseman GA, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol 1999; 17:3793-803.
15. Witzig TE, Molina A, Gordon LI, et al. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with Yttrium 90 Ibritumomab Tiuxetan. Cancer 2007; 109:1804-10. (Pubitemid 46668544)
16. Witzig TE, Flinn IF, Gordon LI, et al. Treatment with ibritumomab tiuxetan ra-dioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002; 20:3262-9.
17. Wiseman GA, Gordon LI, Multani PS, et al. Ibritumomab tiuxetan radioimmuno-therapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 2002; 99:4336-42.
18. Emmanouilides C, Witzig TE, Gordon LI, et al. Treatment with yttrium 90 ibri-tumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma. Leuk Lymphoma 2006; 47:629-36.
19. Tobinai K, Watanabe T, Ogura M, et al. Japanese phase II study of 90Y-ibritu-momab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma. Cancer Sci 2009; 100:158-64.
20. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17:3835-49.
21. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group [erratum in: J Clin Oncol 2000; 18:2351
22. J Clin Oncol 1999; 17:1244.
23. Bendandi M. Aiming at a curative strategy for follicular lymphoma. CA Cancer J Clin 2008; 58:305-17.
24. Conti PS. Radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin): the role of the nuclear medicine physician. Semin Nucl Med 2004; 34:2-3.
25. Tedder TF, Boyd AW, Freedman AS, et al. The B cell surface molecule B1 is functionally linked with B cell activation and differentiation. J Immunol 1985; 135:973-9.
26. Chapuy B, Hohloch K, Trumper L. Yttrium 90 ibritumomab tiuxetan (Zevalin): A new bullet in the fight against malignant lymphoma? Biotechnol J 2007; 2:1435-43.
27. Emmanouilides C. Radioimmunotherapy for non-hodgkin lymphoma: Historical prospective and current status. J Clin Exp Hematop 2007; 47:43-60.
28. White CA, Halpern SE, Parker BA, et al. Radioimmunotherapy of relapsed B-cell lymphoma with yttrium 90 anti-idiotype monoclonal antibodies. Blood 1996; 87:3640-9.
29. Morschhauser F, Radford J, Van Hoof A, et al. Phase II trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008; 26:5156-64.
30. Zinzani PL, Tani M, Pulsoni A, et al. Fludarabine and mitoxantrone followed by yttium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ). Lancet Oncol 2008; 9:352-8.
31. Hainsworth JD, Spigel DR, Markus TM, et al. Rituximab plus short-duration chemotherapy followed by Yttrium-90 ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium. Clin Lymphoma Myeloma 2009; 9:223-8.